These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18836339)

  • 21. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
    Sengeløv L; Geertsen PF;
    Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent progress in the management of advanced renal cell carcinoma.
    Garcia JA; Rini BI
    CA Cancer J Clin; 2007; 57(2):112-25. PubMed ID: 17392388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant and neoadjuvant therapy in renal cell carcinoma.
    Jonasch E; Tannir NM
    Cancer J; 2008; 14(5):315-9. PubMed ID: 18836336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for renal cell cancer.
    Yang JC; Childs R
    J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.
    Bukowski RM
    Cancer; 2009 May; 115(10 Suppl):2273-81. PubMed ID: 19402065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal cell carcinoma.
    Mulders PF
    World J Urol; 2008 Apr; 26(2):113. PubMed ID: 18389254
    [No Abstract]   [Full Text] [Related]  

  • 28. Systemic Therapy for Metastatic Renal-Cell Carcinoma.
    Choueiri TK; Motzer RJ
    N Engl J Med; 2017 Jan; 376(4):354-366. PubMed ID: 28121507
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.
    Santoni M; De Tursi M; Felici A; Lo Re G; Ricotta R; Ruggeri EM; Sabbatini R; Santini D; Vaccaro V; Milella M
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):697-709. PubMed ID: 23773104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is age a prognostic factor for treatment outcome in renal cell cancer-A comprehensive review.
    Ramos-Barcelo E; Rioja J; Pes PL; de la Rosette JJ; de Reijke TM
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):83-9. PubMed ID: 19328009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
    Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
    Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VEGFR-targeted therapy.
    Flaherty KT
    Clin Adv Hematol Oncol; 2005 May; 3(5):371-2. PubMed ID: 16167010
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma.
    Richey SL; Hutson TE
    Cancer J; 2013; 19(4):307-10. PubMed ID: 23867511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic metastasis from renal carcinoma managed by Whipple resection. A case report and literature review of metastatic pattern, surgical management and outcome.
    Machado NO; Chopra P
    JOP; 2009 Jul; 10(4):413-8. PubMed ID: 19581746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives].
    Oudard S; Cornu JN; Rouprêt M; Patard JJ
    Prog Urol; 2008 Jul; 18 Suppl 4():S77-80. PubMed ID: 18706375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic factors in kidney cancer].
    Patard JJ
    Prog Urol; 2007 Feb; 17(1 Suppl 1):139-43. PubMed ID: 17571637
    [No Abstract]   [Full Text] [Related]  

  • 39. [Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].
    Büchler T; Finek J; Hájek J; Kocák I; Kubácková K; Lakomý R; Melichar B; Petruzelka L; Poprach A; Siffnerová M; Tomásek J; Vyzula R; Zemanová M;
    Klin Onkol; 2013; 26(1):55-7. PubMed ID: 23607143
    [No Abstract]   [Full Text] [Related]  

  • 40. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
    Patard JJ
    Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.